Brentuximab vedotin in transplant-naïve patients with relapsed or refractory Hodgkin lymphoma: Analysis of two phase I studies

Andres Forero-Torres, Michelle Fanale, Ranjana Advani, Nancy L. Bartlett, Joseph D. Rosenblatt, Dana A. Kennedy, Anas Younes

Research output: Contribution to journalArticlepeer-review

39 Scopus citations


Background. Brentuximab vedotin is an antibody-drug conjugate designed to selectively deliver monomethyl auristatin E, a microtubule-disrupting agent, to CD30-expressing cells. Brentuximab vedotin induces durable objective responses in patients with relapsed or refractory Hodgkin lymphoma (HL) after autologous stem cell transplantation (ASCT). The objective of this post-hoc analysis was to characterize the safety and efficacy of brentuximab vedotin for patients with relapsed or refractoryHLwho refused or were ineligible for ASCT. Methods. This case series included 20 transplant-naïve patients who were enrolled in two phase I multicenter studies. Patients received brentuximab vedotin intravenously every 3 weeks or every week for 3 out of 4 weeks. Results. The majority of patients were transplant-naïve because of chemorefractory disease. Median age was 31.5 years (range, 12-87 years). Treatment-emergent adverse events in >20% of patients were peripheral neuropathy, fatigue, nausea, pyrexia, diarrhea, weight decreased, anemia, back pain, decreased appetite, night sweats, and vomiting; most events were grade 1 or 2. Six patients obtained objective responses: two complete remissions and four partial remissions. Median duration of response was not met; censored durations ranged from >6.8 to >13.8 months. Three of six responders subsequently received ASCT. Conclusion. Brentuximab vedotin was associated with manageable adverse events in transplant-naïve patients with relapsed or refractory HL. The objective responses observed demonstrate that antitumor activity is not limited to patients who received brentuximab vedotin after ASCT. The promising activity observed in this population warrants further study.

Original languageEnglish
Pages (from-to)1073-1080
Number of pages8
Issue number8
StatePublished - Aug 2012


  • Antigens CD30
  • Hodgkin disease
  • Immunoconjugates
  • Monoclonal antibodies


Dive into the research topics of 'Brentuximab vedotin in transplant-naïve patients with relapsed or refractory Hodgkin lymphoma: Analysis of two phase I studies'. Together they form a unique fingerprint.

Cite this